The Halyard Health Inc. (HYH) Stake Increased by UBS Asset Management Americas Inc.

The Halyard Health Inc. (HYH) Stake Increased by UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. increased its position in Halyard Health Inc. (NYSE:HYH) by 6.0% during the second quarter, Holdings Channel reports. The firm owned 47,071 shares of the company’s stock after buying an additional 2,683 shares during the period. UBS Asset Management Americas Inc. owned 0.10% of Halyard Health worth $1,530,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in HYH. Chicago Equity Partners LLC bought a new stake in Halyard Health during the second quarter worth approximately $7,189,000. Emerald Acquisition Ltd. bought a new stake in Halyard Health during the second quarter worth approximately $4,905,000. Bogle Investment Management L P DE bought a new stake in Halyard Health during the first quarter worth approximately $1,456,000. Ameriprise Financial Inc. boosted its stake in Halyard Health by 37.7% in the second quarter. Ameriprise Financial Inc. now owns 161,795 shares of the company’s stock worth $5,260,000 after buying an additional 44,268 shares during the period. Finally, Credit Agricole S A boosted its stake in Halyard Health by 137.7% in the first quarter. Credit Agricole S A now owns 57,038 shares of the company’s stock worth $1,639,000 after buying an additional 33,038 shares during the period. Institutional investors own 82.93% of the company’s stock.

Halyard Health Inc. (NYSE:HYH) traded up 0.03% during trading on Thursday, hitting $34.18. 46,366 shares of the stock traded hands. The stock’s market cap is $1.60 billion. The firm’s 50-day moving average is $35.04 and its 200-day moving average is $32.80. Halyard Health Inc. has a 12 month low of $22.76 and a 12 month high of $37.31.

Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, August 3rd. The company reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.09. Halyard Health had a negative net margin of 27.63% and a positive return on equity of 8.91%. The firm had revenue of $400 million for the quarter, compared to analyst estimates of $383.08 million. During the same period in the prior year, the firm earned $0.52 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, analysts forecast that Halyard Health Inc. will post $1.82 EPS for the current year.

A number of analysts recently commented on HYH shares. Deutsche Bank AG lifted their target price on shares of Halyard Health from $36.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, August 10th. Zacks Investment Research cut shares of Halyard Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 5th. Stifel Nicolaus lifted their price objective on shares of Halyard Health from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, August 4th. Finally, TheStreet upgraded shares of Halyard Health from a “sell” rating to a “hold” rating in a research note on Friday, July 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Halyard Health currently has a consensus rating of “Buy” and a consensus target price of $36.00.

Halyard Health Company Profile

Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.

Related posts

Leave a Comment